Many treatments are available, and with the popularity of online and mail-order services in recent years, two leaders are BlueChew and Hims. Both companies offer different ED treatments and a ...

Rugiet, BlueChew, and Hims are leading the way, offering innovative solutions that cater to different preferences and ...

We review and compare the best options from Hims, Bluechew, and Ro. Erectile dysfunction (ED) meds like Viagra have a long and storied history. Sildenafil (Viagra), in particular, was first ...

That’s how long it’s been since Tom Izzo last hoisted a national championship trophy and apparently, the last time he’s felt anything.

Shares of the health and wellness platform operator skyrocketed more than 670% between Jan. 1, 2024, and Feb. 19, 2025.

Hims & Hers (NYSE: HIMS) has seen incredibly high growth, but the market is skeptical that will continue. In this video, ...

I think Hims & Hers Health has achieved "escape velocity", with a 95%+ increase year-over-year in Q4 2024 and expected 56%-63% growth in 2025, net of GLP-1 issues. The market overreacted to HIMS ...

Hims & Hers has risen 70% since November 2024, outperforming the S&P 500, despite recent regulatory challenges impacting its compounded semaglutide product. Its diversified portfolio in men's and ...

Hims & Hers Health (HIMS) stock enjoyed a 10% jump in price last week on news that the company plans to continue offering compounded versions of Ozempic and Wegovy. This approach is in response to ...

Hims & Hers Health Inc. (NYSE:HIMS) Hims & Hers rallied by 5.72 percent on Friday to finish at $34.75 apiece as investors loaded up on its shares despite the lack of catalysts to boost investing ...

“RKLX and HIMZ offer compelling opportunities for investors seeking amplified exposure to Rocket Lab and Hims & Hers, two companies driving innovation in their respective industries,” said ...